# DAHANCA 28A: Phase I/II Study on Accelerated, Hyperfractionated Radiotherapy With Concomitant Cisplatin and Nimorazole

> **NCT01733823** · PHASE1,PHASE2 · COMPLETED · sponsor: **Danish Head and Neck Cancer Group** · enrollment: 31 (actual)

## Conditions studied

- HNSCC,Larynx, Pharynx and Oral Cavity

## Interventions

- **RADIATION:** 76 Gy/ 56 fx/ 10/W with cisplatin 40 mg/m2/W and nimorazole

## Key facts

- **NCT ID:** NCT01733823
- **Lead sponsor:** Danish Head and Neck Cancer Group
- **Sponsor class:** NETWORK
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2013-01
- **Primary completion:** 2016-03
- **Final completion:** 2016-03
- **Target enrollment:** 31 (ACTUAL)
- **Last updated:** 2017-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01733823

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01733823, "DAHANCA 28A: Phase I/II Study on Accelerated, Hyperfractionated Radiotherapy With Concomitant Cisplatin and Nimorazole". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01733823. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*